Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  He, Lijie ^a   Teng, Yuee ^a   Jin, Bo ^a   Zhao, Mingfang ^a   Yu, Ping ^a   Hu, Xuejun ^a   Zhang, Jingdong ^a   Li, Songbai ^a   Gao, Yaling ^b   Liu, Yunpeng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b The Oncology Hospital of Liaoning Province in China   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME; CHINA; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG EFFECT; HEALTH SURVEY; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; DISEASE-FREE SURVIVAL; FEMALE; HEALTH STATUS INDICATORS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 78649988304     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-681     Document Type: Article

References (39)

1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
2. Lara PN, Redman MW, Karen K, Edelman MJ, Williamson SK, Crowley JJ, Gandara DR. Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non-Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials. J Clin Oncol 2008, 26:463-467. 10.1200/JCO.2007.13.0344, 18202421.
3. Chikako S, Hans J, Thomas H, Torkzad MR, Katarina B, Yvonne E, Elisabeth B, Hirofumi F, Atsushi K, Lennart B. Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and Limitations. Radiographics 2008, 28:329-344. 10.1148/rg.282075068, 18349443.
4. Karnofsky DA. Meaningful clinical classification of therapeutic responses to anticancer drugs. Clin Pharmacol Ther 1961, 2:709-712.
5. Moertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 1976, 38:388-394. 10.1002/1097-0142(197607)38:1<388::AID-CNCR2820380156>3.0.CO;2-A, 947531.
6. James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999, 91:523-528. 10.1093/jnci/91.6.523, 10088622.
7. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol 2001, 74:983-986.
8. Sirohi B, Ashley S, Norton A, Popat S, Hughes S, Papadopoulos P, Priest K, O'Brien M. Early response to platinum-based first-Line chemotherapy in non-small cell lung cancer may predict survival. J Thorac Oncol 2007, 2:735-740. 10.1097/JTO.0b013e31811f3a7d, 17762340.
9. Therasse P. Measuring the clinical response. What does it mean?. Eur J Cancer 2002, 38:1817-1823. 10.1016/S0959-8049(02)00182-X, 12204662.
10. Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, Brouchet L, Quoix E, Westeel V, Le C. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000, 18:2981-2989.
11. Fidias P, Dakhil SR, Lyss AP, Loesch DM, Waterhouse D, Cunneen J, Ye Z, Tai F, Obasaju CK, Schiller JH. Updated report of a phase III study of induction therapy with gemcitabine + carboplatin (GC) followed by either delayed vs immediate second line therapy with docetaxel (D) in advanced non small cell lung cancer (NSCLC) [Abstract]. J Clin Oncol 2006, 24:s18.
12. Victorson D, Soni M, Cella D. Metaanalysis of the correlation between radiographic tumor response and patient-reported outcomes. Cancer 2006, 106:494-504. 10.1002/cncr.21637, 16353212.
13. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Annals of Oncology 2008, 19:508-515. 10.1093/annonc/mdm496, 17998284.
14. Piessevaux H, Buyse M, De Roock W, Prenen H, Schlichting M, Van Cutsem E, Tejpar S. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Annals of Oncology 2009, 20:1375-1382. 10.1093/annonc/mdp011, 19465422.
15. Piessevaux H, De Roock W, Van Cutsem E, Tejpar S. Use of tumor size decrease at 6 weeks (w) to predict response (OR), time to progression (TTP), and survival (OS) in chemorefractory metastatic colorectal cancer (cmCRC) treated with cetuximab (CTX) (BOND trial) [abstract]. J Clin Oncol 2008, 26:s15.
16. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007, 25:1753-1759. 10.1200/JCO.2006.07.3049, 17470865.
17. Marc B, Tomasz B, Kevin C, Stefan M, Sargent DJ, Miller LL, Elfring GL, Jean-Pierre P, Pascal P. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007, 25:5218-5224. 10.1200/JCO.2007.11.8836, 18024867.
18. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007, 25:4562-4568. 10.1200/JCO.2006.08.1935, 17876010.
19. Carroll KJ. Analysis of progression-free survival in oncology trials: some common statistical issues. Pharm Stat 2007, 6:99-113. 10.1002/pst.251, 17243095.
20. Shi Q, Sargent DJ. Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. Int J Clin Oncol 2009, 14:102-111. 10.1007/s10147-009-0885-4, 19390940.
21. Levin VA, Ictech S, Hess KR. Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer 2007, 7:106. 10.1186/1471-2407-7-106, 1919386, 17587447.
22. Methy N, Bedenne L, Bonnetain F. Validation of surrogate endpoints in digestive oncology. Bull Cancer 2009, 96:591-595.
23. Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, et al. Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res 2007, 13:S4583-S4588. 10.1158/1078-0432.CCR-07-0716, 17671145.
24. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000, 356:373-378. 10.1016/S0140-6736(00)02528-9, 10972369.
25. Birchard KR, Hoang JK, Herndon JE, Patz EF. Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer 2009, 115:581-586. 10.1002/cncr.24060, 19117348.
26. Cesano A, Lane SR, Poulin R, Ross G, Fields SZ. Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol 1999, 15:1233-1238.
27. Cesano A, Lane SR, Ross GA, Fields SZ. Stabilization of disease as an indicator of clinical benefit associated with chemotherapy in non-small cell lung cancer patients. Int J Oncol 2000, 17:587-590.
28. Liu-Jarin X, Stoopler MB, Raftopoulos H, Ginsburg M, Gorenstein L, Borczuk AC. Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol 2003, 16:1102-1108. 10.1097/01.MP.0000096041.13859.AB, 14614049.
29. Esendagli G, Bruderek K, Goldmann T, Busche A, Branscheid D, Vollmer E, Brandau S. Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 2008, 59:32-40. 10.1016/j.lungcan.2007.07.022, 17825949.
30. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002, 38(Suppl 5):60-65.
31. Junker K, Langner K, Klinke F, Bosse U, Thomas M. Grading of tumor regression in non-small cell lung cancer: morphology and prognosis. Chest 2001, 120:1584-1591. 10.1378/chest.120.5.1584, 11713138.
32. Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Mueller KM. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 1997, 123:469-477. 10.1007/BF01192200, 9341895.
33. Weber WA. Assessing tumor response to therapy. J Nucl Med 2009, 50(Suppl 1):1S-10S. 10.2967/jnumed.108.057174, 19380403.
34. Ollivier L, Thiesse P, Di Stefano D, Vincent C. Measurement of tumour response to cancer treatment: morphologic imaging role. Bull Cancer 2007, 94:171-177.
35. Schuetze SM, Baker LH, Benjamin RS, Canetta R. Selection of response criteria for clinical trials of sarcoma treatment. The Oncologist 2008, 13(Suppl 2):32-40. 10.1634/theoncologist.13-S2-32, 18434637.
36. de Geus-Oei LF, van der Heijden HF, Visser EP, Hermsen R, van-Hoorn BA, Timmer-Bonte JN, Willemsen AT, Pruim J, Corstens FH, Krabbe PF, Oyen WJ. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med 2007, 48:1592-1598. 10.2967/jnumed.107.043414, 17873138.
37. Hoekstra CJ, Stroobants SG, Smit EF, Johan V, van Tinteren H, Postmus PE, Golding RP, Biesma B, Schramel FJHM, van Zandwijk N, Lammertsma AA, Hoekstra OS. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:8362-8370. 10.1200/JCO.2005.01.1189, 16293866.
38. Oremek GM, Sauer-Eppel H, Bruzdziak TH. Value of tumour and inflammatory markers in lung cancer. Anticancer Res 2007, 27:1911-1915.
39. Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH, Patz EF. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006, 107:2866-2872. 10.1002/cncr.22282, 17099880.